-
Something wrong with this record ?
Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers
D. Lizoňová, J. Mužík, M. Šoltys, J. Beránek, SG. Kazarian, F. Štěpánek,
Language English Country Netherlands
Document type Journal Article
- MeSH
- Adsorption MeSH
- Biological Availability MeSH
- Calorimetry, Differential Scanning MeSH
- Chemistry, Pharmaceutical methods MeSH
- Ibuprofen administration & dosage chemistry MeSH
- Crystallization MeSH
- Microscopy, Electron, Scanning MeSH
- Drug Carriers chemistry MeSH
- Silicon Dioxide chemistry MeSH
- Porosity MeSH
- Solubility MeSH
- Spectroscopy, Fourier Transform Infrared MeSH
- Drug Liberation MeSH
- Water chemistry MeSH
- Hot Temperature MeSH
- Publication type
- Journal Article MeSH
Drug amorphisation by loading to inorganic mesoporous carriers represents an emerging area of improving the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs). In this work, for the first time, a molecular-level insight into the process of API loading to mesoporous SiO2 (silica) carriers by the hot-melt impregnation method and its subsequent release during dissolution was obtained using ATR-FTIR spectroscopic imaging. A physical mixture of ibuprofen crystals and mesoporous silica particles was heated and the dynamics of melt loading into the silica pore structure was directly observed in situ by ATR-FTIR spectroscopic imaging. The loss of crystallinity, the redistribution of the API in the silica pore network and the subsequent stabilisation of the amorphous form upon cooling were proven. The API was involved in two different kinds of molecular-level interactions: API dimers in the amorphous bulk, and individual API molecules adsorbed on the silica surface. The melt-loaded silica carriers were comprehensively characterised by DSC, SEM and dissolution tests, which proved dissolution rate enhancement due to amorphisation of the API. Drug release form the hot-melt loaded mesoporous silica carriers was observed in real time and the conditions leading to local re-crystallisation of super-saturated solution of the API were identified.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000554
- 003
- CZ-PrNML
- 005
- 20190118113653.0
- 007
- ta
- 008
- 190107s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2018.07.013 $2 doi
- 035 __
- $a (PubMed)30012403
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Lizoňová, D $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technicka 3, 166 28 Prague 6, Czech Republic; Zentiva k.s., U Kabelovny 130, Prague 10, Czech Republic.
- 245 10
- $a Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers / $c D. Lizoňová, J. Mužík, M. Šoltys, J. Beránek, SG. Kazarian, F. Štěpánek,
- 520 9_
- $a Drug amorphisation by loading to inorganic mesoporous carriers represents an emerging area of improving the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs). In this work, for the first time, a molecular-level insight into the process of API loading to mesoporous SiO2 (silica) carriers by the hot-melt impregnation method and its subsequent release during dissolution was obtained using ATR-FTIR spectroscopic imaging. A physical mixture of ibuprofen crystals and mesoporous silica particles was heated and the dynamics of melt loading into the silica pore structure was directly observed in situ by ATR-FTIR spectroscopic imaging. The loss of crystallinity, the redistribution of the API in the silica pore network and the subsequent stabilisation of the amorphous form upon cooling were proven. The API was involved in two different kinds of molecular-level interactions: API dimers in the amorphous bulk, and individual API molecules adsorbed on the silica surface. The melt-loaded silica carriers were comprehensively characterised by DSC, SEM and dissolution tests, which proved dissolution rate enhancement due to amorphisation of the API. Drug release form the hot-melt loaded mesoporous silica carriers was observed in real time and the conditions leading to local re-crystallisation of super-saturated solution of the API were identified.
- 650 _2
- $a adsorpce $7 D000327
- 650 _2
- $a biologická dostupnost $7 D001682
- 650 _2
- $a diferenciální skenovací kalorimetrie $7 D002152
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a krystalizace $7 D003460
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a vysoká teplota $7 D006358
- 650 _2
- $a ibuprofen $x aplikace a dávkování $x chemie $7 D007052
- 650 _2
- $a mikroskopie elektronová rastrovací $7 D008855
- 650 _2
- $a poréznost $7 D016062
- 650 _2
- $a oxid křemičitý $x chemie $7 D012822
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a spektroskopie infračervená s Fourierovou transformací $7 D017550
- 650 _2
- $a voda $x chemie $7 D014867
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mužík, J $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technicka 3, 166 28 Prague 6, Czech Republic.
- 700 1_
- $a Šoltys, M $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technicka 3, 166 28 Prague 6, Czech Republic.
- 700 1_
- $a Beránek, J $u Zentiva k.s., U Kabelovny 130, Prague 10, Czech Republic.
- 700 1_
- $a Kazarian, S G $u Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom. Electronic address: s.kazarian@imperial.ac.uk.
- 700 1_
- $a Štěpánek, F $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technicka 3, 166 28 Prague 6, Czech Republic. Electronic address: Frantisek.Stepanek@vscht.cz.
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 130, č. - (2018), s. 327-335
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30012403 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190118113907 $b ABA008
- 999 __
- $a ok $b bmc $g 1364613 $s 1038677
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 130 $c - $d 327-335 $e 20180721 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $a Pubmed-20190107